Ustekinumab is more effective than azathioprine to prevent endoscopic postoperative recurrence in Crohn's disease.

United European Gastroenterol J · 2021 · PMC8259431 · PMID 33951350

Europe PMC DOI

hedged sentence

0.0660

closest p · 1.3× alpha

0.0660

boldest claim

The sentences

did not reach statistical significancep = 0.066so close (0.05 < p ≤ 0.1)

Even though it did not reach statistical significance, we observed a numerically twofold lower rate of i2b‐recurrence in the ustekinumab group (after IPTW: 20.8% vs. 42.5, p = 0.066).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.